211 related articles for article (PubMed ID: 22542009)
1. Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors.
Rew Y; DeGraffenreid M; He X; Jaen JC; McMinn DL; Sun D; Tu H; Ursu S; Powers JP
Bioorg Med Chem Lett; 2012 Jun; 22(11):3786-90. PubMed ID: 22542009
[TBL] [Abstract][Full Text] [Related]
2. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Hofer S; Kratschmar DV; Schernthanner B; Vuorinen A; Schuster D; Odermatt A; Easmon J
Bioorg Med Chem Lett; 2013 Oct; 23(19):5397-400. PubMed ID: 23981897
[TBL] [Abstract][Full Text] [Related]
4. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
[TBL] [Abstract][Full Text] [Related]
5. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.
Shah U; Boyle CD; Chackalamannil S; Baker H; Kowalski T; Lee J; Terracina G; Zhang L
Bioorg Med Chem Lett; 2010 Mar; 20(5):1551-4. PubMed ID: 20149650
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT
Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1.
Xia G; Liu L; Xue M; Liu H; Yu J; Li P; Chen Q; Xiong B; Liu X; Shen J
Mol Cell Endocrinol; 2012 Jul; 358(1):46-52. PubMed ID: 22410288
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1).
Sun D; Wang Z; Cardozo M; Choi R; Degraffenreid M; Di Y; He X; Jaen JC; Labelle M; Liu J; Ma J; Miao S; Sudom A; Tang L; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2009 Mar; 19(5):1522-7. PubMed ID: 19181519
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structural activity relationship of 11beta-HSD1 inhibitors with novel adamantane replacements.
Yeh VS; Kurukulasuriya R; Madar D; Patel JR; Fung S; Monzon K; Chiou W; Wang J; Jacobson P; Sham HL; Link JT
Bioorg Med Chem Lett; 2006 Oct; 16(20):5408-13. PubMed ID: 16890427
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of heterocycle containing adamantane 11beta-HSD1 inhibitors.
Yeh VS; Patel JR; Yong H; Kurukulasuriya R; Fung S; Monzon K; Chiou W; Wang J; Stolarik D; Imade H; Beno D; Brune M; Jacobson P; Sham H; Link JT
Bioorg Med Chem Lett; 2006 Oct; 16(20):5414-9. PubMed ID: 16899366
[TBL] [Abstract][Full Text] [Related]
11. Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Su X; Pradaux-Caggiano F; Thomas MP; Szeto MW; Halem HA; Culler MD; Vicker N; Potter BV
ChemMedChem; 2010 Jul; 5(7):1026-44. PubMed ID: 20486152
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity relationships of ent-Kaurene diterpenoids as potent and selective 11β-HSD1 inhibitors: potential impact in diabetes.
Deng X; Shen Y; Yang J; He J; Zhao Y; Peng LY; Leng Y; Zhao QS
Eur J Med Chem; 2013 Jul; 65():403-14. PubMed ID: 23747808
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors.
Sun D; Wang Z; Caille S; DeGraffenreid M; Gonzalez-Lopez de Turiso F; Hungate R; Jaen JC; Jiang B; Julian LD; Kelly R; McMinn DL; Kaizerman J; Rew Y; Sudom A; Tu H; Ursu S; Walker N; Willcockson M; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2011 Jan; 21(1):405-10. PubMed ID: 21093258
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
16. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.
Siu M; Johnson TO; Wang Y; Nair SK; Taylor WD; Cripps SJ; Matthews JJ; Edwards MP; Pauly TA; Ermolieff J; Castro A; Hosea NA; LaPaglia A; Fanjul AN; Vogel JE
Bioorg Med Chem Lett; 2009 Jul; 19(13):3493-7. PubMed ID: 19473839
[TBL] [Abstract][Full Text] [Related]
17. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders.
Yoon DS; Wu SC; Seethala R; Golla R; Nayeem A; Everlof JG; Gordon DA; Hamann LG; Robl JA
Bioorg Med Chem Lett; 2014 Nov; 24(21):5045-9. PubMed ID: 25266782
[TBL] [Abstract][Full Text] [Related]
20. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
